Discovery of Potent and Selective Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK1/2 Inhibitors with Significant Efficacy against Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c03316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Tingting Qiu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Pharmacy, Ocean University of China and Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Cen…. Hauptthemen laut MEDLINE: Thiadiazoles, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Imidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Taishan Scholar Project of Shandong Province, Qingdao National Laboratory for Marine Science and Technology, National Natural Science Foundation of China.
Abstract (Originalsprache)
Mitogen-activated protein kinase-interacting kinases (MNK1/2) have emerged as promising therapeutic targets for metabolic dysfunction-associated steatotic liver disease (MASLD). Through scaffold-conservative optimization of an imidazo[2,1- b ][1,3,4]thiadiazole core, we identified HD202A as a highly potent MNK1/2 inhibitor (IC 50 = 6.1/8.1 nM) with favorable kinome selectivity within the tested kinase panel, oral bioavailability (F = 42.1%), and favorable pharmacokinetic properties. In a high-fat-diet induced MASLD mice, HD202A markedly reduced body-weight gain, hepatic triglyceride accumulation, and serum lipids while improving glucose tolerance, insulin sensitivity, and inflammatory profiles. Mechanistically, HD202A suppressed MNK-eIF4E signaling, downregulated perilipin 2 and stearoyl-coenzyme A desaturase 1, upregulated adipose triglyceride lipase and peroxisome proliferator-activated receptor gamma coactivator 1α, and enhanced mitochondrial fatty-acid oxidation and redox homeostasis. These findings validate MNK inhibition as a viable strategy for MASLD and establish HD202A as a promising lead compound for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine and Pharmacy, Ocean University of China and Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao 266003, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, Qingdao 266003, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao 266237, China.
- Lifelong Health, South Australian Health & Medical Research Institute, North Terrace, Adelaide SA5000, Australia.
Förderung
- Taishan Scholar Project of Shandong Province
- Qingdao National Laboratory for Marine Science and Technology
- National Natural Science Foundation of China
- Key Project of Greater, Bay Area Institute of Precision Medicine
Zitieren
APA
Qiu, T., Jin, X., Yin, R., Wang, H., Wei, X., Xue, L., Yu, R., Wang, X., Proud, C., & Jiang, T. (2026). Discovery of Potent and Selective Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK1/2 Inhibitors with Significant Efficacy against Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03316
Vancouver
Qiu T, Jin X, Yin R, Wang H, Wei X, Xue L, et al. Discovery of Potent and Selective Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK1/2 Inhibitors with Significant Efficacy against Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03316
BibTeX
@article{Qiu2026,
author = {Qiu, Tingting and Jin, Xin and Yin, Ruijuan and Wang, Hao and Wei, Xianfeng and Xue, Liang and Yu, Rilei and Wang, Xuemin and Proud, Christopher and Jiang, Tao},
title = {Discovery of Potent and Selective Imidazo[2,1- b ][1,3,4]thiadiazole-Based MNK1/2 Inhibitors with Significant Efficacy against Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c03316}
}
EUVIMED